Evidence map›Paper›PMID 41402577›Full record

ArticleDrug delivery and translational research2026

Functional and therapeutic effects of Glabrescione B delivery by liposomes on Hedgehog-dependent tumors.

Paola Infante, Raffaella Daniele, Marta Bottero, Mariagrazia Longo, Francesca Bufalieri, Ludovica Lospinoso Severini, Cristiano Pesce, Agnese Fragassi, Daniela Gabbia, Shirin Navacci and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Paola Infante *Department of Molecular Medicine, Sapienza University, Rome, Italy.
Raffaella Daniele *Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Marta Bottero *Department of Molecular Medicine, Sapienza University, Rome, Italy.
Mariagrazia LongoDepartment of Molecular Medicine, Sapienza University, Rome, Italy.
Francesca BufalieriDepartment of Molecular Medicine, Sapienza University, Rome, Italy.
Ludovica Lospinoso SeveriniDepartment of Molecular Medicine, Sapienza University, Rome, Italy.
Cristiano PesceDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Agnese FragassiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Daniela GabbiaDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Shirin NavacciDepartment of Molecular Medicine, Sapienza University, Rome, Italy.
Irene BasiliInstitut Curie, PSL Research University, INSERMU1330/CNRS EMR 8001. Children's Oncology Research Unit (CONCERT), Paris, France.
Gennaro AdabboDepartment of Molecular Medicine, Sapienza University, Rome, Italy.
Silvia CammaroneDipartimento Di Chimica E Tecnologie del Farmaco, Sapienza University, Rome, Italy.
Gabriele CianfoniDipartimento Di Chimica E Tecnologie del Farmaco, Sapienza University, Rome, Italy.
Francesca GhirgaDipartimento Di Chimica E Tecnologie del Farmaco, Sapienza University, Rome, Italy.
Mattia MoriDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100, Siena, Italy.
Sara De MartinDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Mariateresa MancusoDivision of Biotechnologies, Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), 00123, Rome, Italy.
Paolo CalicetiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Simonetta PazzagliaDivision of Biotechnologies, Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), 00123, Rome, Italy.
Stefano SalmasoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy. stefano.salmaso@unipd.it.
Lucia Di MarcotullioDepartment of Molecular Medicine, Sapienza University, Rome, Italy. lucia.dimarcotullio@uniroma1.it.ORCID http://orcid.org/0000-0003-0274-7178

Funding

Fondazione AIRC per la ricerca sul cancro ETS IG20801Fondazione AIRC per la ricerca sul cancro ETS IG29329
6 · The paper itself

Abstract

Aberrant Hedgehog (HH) signaling pathway is responsible of tumorigenesis of medulloblastoma (MB) and basal cell carcinoma (BCC), two aggressive malignancies with limited therapeutic options. Targeting Gli1, the final and powerful effector of HH signaling, emerged as a valuable strategy for the treatment of HH-dependent tumors. Among Gli1 inhibitors, Glabrescione B (GlaB), is a small molecule that directly inhibits Gli1/DNA interaction, which showed promising pre-clinical results. However, poor solubility limits its clinical translation. To overcome this issue, here we develop a liposomal formulation of GlaB (Lipo/GlaB) with optimized composition to enhance drug loading, controlled release, storage stability and pharmacokinetic performance. Among various formulations, liposomes composed of EPC and cholesterol (95:5 mol/mol%) achieves high GlaB loading efficiency and stability upon lyophilization. Lipo/GlaB inhibits Gli1 transcriptional activity more potently than free GlaB and significantly reduces the expression of HH target genes. Notably, Lipo/GlaB remarkably reduces the tumor growth in HH-driven MB and BCC in in vitro and in vivo models, correlating with decreased HH signaling. Further, pharmacokinetic studies in mice revealed improved plasma disposition, higher AUC, and slower elimination for Lipo/GlaB compared to the free drug. These findings support the therapeutic value of Lipo/GlaB as a selective and potent strategy for targeting HH-dependent cancers, offering improved biopharmaceutical properties and in vivo efficacy compared to non-formulated GlaB.

Indexed as

Antineoplastic AgentsBasal Cell CarcinomaCerebellar NeoplasmsHedgehog ProteinsMedulloblastomaSkin NeoplasmsAnimalsCell Line, TumorFemaleHumansLiposomesMiceSignal TransductionZinc Finger Protein GLI1Antineoplastic AgentsGli1 protein, mouseHedgehog ProteinsLiposomesZinc Finger Protein GLI1Basal Cell CarcinomaGli1 inhibitorsHedgehog signalingLiposomal deliveryMedulloblastoma

Identifiers

PMID41402577
PMCPMC13294236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.